Flavanone compound and uses thereof

ABSTRACT

Each of an antioxidant, an antimicrobial agent, an antitumor agent, a food and beverage product, cosmetics, a quasi-drug and a pharmaceutical of the present invention contains a new flavanone compound represented by the following structural formula:  
                 
Alternatively, each of an antioxidant, an antimicrobial agent, an antitumor agent, a food and beverage product, cosmetics, a quasi-drug and a pharmaceutical of the present invention contains at least one flavanone compound selected from the group consisting of nymphaeol-A, nymphaeol-B, and nymphaeol-C.

TECHNICAL FIELD

The present invention relates to a new flavanone compound, and anantioxidant, an antimicrobial agent, an antitumor agent, a food andbeverage product, cosmetics, a quasi-drug, and a pharmaceutical each ofwhich contains the flavanone compound.

BACKGROUND ART

As known flavanone compounds, nymphaeol-A, nymphaeol-B, and nymphaeol-Ccan be enumerated. Regarding these known flavanone compounds, see “K.Yakushijin, K. Shibayama, H. Murata and H. Furukawa: Newprenylflavanones from Hernandia nymphaefolia(presl) Kubitzki,Heterocycles, 14, 397-402, 1980”, “W. R. Phillips, N. J. Baj, A. A. L.Gunatilaka and D. G. I. Kingston: C-Geranyl compounds from Mimulusclevelandii, J. Nat. Prod., 59, 495-497, 1996”, and “M. H. Tseng, C. H.Chou, Y. M. Chen and Y. H. Kuo: Allelopathic prenylflavanones from thefallen leaves of Macaranga tanarius, J. Nat. Prod., 64, 827-828, 2001”.Nymphaeol-A is isolated from Hernandia nymphaefolia(presl) Kubitzki, orMimulus clevelandii. Nymphaeol-B is isolated from Hernandianymphaefolia(presl) Kubitzki. Nymphaeol-C is isolated from Hernandianymphaefolia(presl) Kubitzki, or Macaranga tanarius. However, thephysiological activities of these flavanone compounds have been hardlyelucidated.

SUMMARY OF THE INVENTION

Accordingly, the present inventors made extensive studies to find theuseful physiological activities of a known flavanone compound, andfurthermore to find the useful physiological activities of a newflavanone compound by isolating the new flavanone compound. The presentinvention is based on findings obtained in this manner. It is a firstobjective of the present invention to provide a new flavanone compoundthat is utilized for various applications such as food and beverages,and a pharmaceutical. It is a second objective of the present inventionto provide applications of a known or new flavanone compound wherein theuseful physiological activities of the flavanone compound are utilized.

In order to accomplish the above objectives, one aspect of the presentinvention provides a flavanone compound represented by the structuralformula:

Another aspect of the present invention provides an antioxidant, anantimicrobial agent, an antitumor agent, a food and beverage product,cosmetics, a quasi-drug, and a pharmaceutical each of which contains theflavanone compound as described above.

Still another aspect of the present invention provides an antioxidant,an antimicrobial agent, an antitumor agent, a food and beverage product,cosmetics, a quasi-drug, and a pharmaceutical each of which contains atleast one flavanone compound selected from nymphaeol-A, nymphaeol-B, andnymphaeol-C.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a table wherein the physicochemical properties of Compound 1in Examples are summarized.

FIG. 2 is a table wherein the NMR data of Compound 1 in the Examples areshown.

FIG. 3 is a table wherein the physicochemical properties of Compound 2in the Examples are summarized.

FIG. 4 is a table wherein the NMR data of Compound 2 in the Examples areshown.

FIG. 5 is a table wherein the physicochemical properties of Compound 3in the Examples are summarized.

FIG. 6 is a table wherein the NMR data of Compound 3 in Examples areshown.

FIG. 7 is a table wherein the physicochemical properties of Compound 4in the Examples are summarized.

FIG. 8 is a table wherein the NMR data of Compound 4 in the Examples areshown.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, a first embodiment of the present invention will beexplained.

A flavanone compound according to the first embodiment is5,7,3′,4′-tetrahydroxy-5′-C-geranylflavanone (isonymphaeol-B), which isrepresented by the structural formula 1:

The flavanone compound has the molecular formula C₂₅H₂₈O₆, a molecularweight of 424, and a melting point of 123 to 126° C. (see FIG. 3). Theflavanone compound is a naturally occurring new compound, which has beenisolated from an Okinawa propolis by the present inventors. Although theflavanone compound has a structural characteristic similar to that oferiodictyol, it has a C-geranyl group at the 5′-position. Thus, it ishigher in lipophilic properties (or membrane permeabilities) thaneriodictyol.

The flavanone compound has as high an anti-oxidant action as eriodictyolor α-tocopherol. In addition, the flavanone compound has an antitumoraction which inhibits the proliferation of cancer cells such as a breastcancer cell. Furthermore, the flavanone compound has an action inducingphysiological cell-death (or apoptosis) in order to remove undesiredcells such as a cancerating abnormal cell, and an aged cell reaching itscellular life span. In addition, the flavanone compound has anantimicrobial action on Gram-positive bacteria such as Staphylococcusaureus, and spore forming bacteria such as Genus Bacillus.

An antioxidant according to the first embodiment contains the flavanonecompound as an active ingredient (or an anti-oxidant component). Theantioxidant may be utilized by adding it to a food and beverage productas a deterioration inhibitor to effectively inhibit deterioration(mainly, oxidation deterioration) of various products, such as theoxidation deterioration of fats and oils, the deterioration of flavorcomponents, the decomposition of a coloring matter, and thediscoloration of coloring matter. In a living body wherein a food andbeverage product such as a health food product, containing theantioxidant, has been orally ingested, the flavanone compound eliminatesactive oxygen so as to exert health-enhancement effects such as anenhancement action for hepatic function, a decrease in acetaldehydetoxicity, an antioxidant action for low-density lipoprotein-cholesterol(LDL), an proliferation-inhibiting action to breast cancer cells, and animprovement in immune function. The antioxidant may be utilized bymaking it contained in cosmetics or a quasi-drug. In that case, itserves for whitening effectiveness and aging protection and the like forthe skin, the oral cavity and the like.

An antimicrobial agent according to the first embodiment contains theflavanone compound as an active ingredient. The antimicrobial agent isutilized by adding it to, for example, a food and beverage product. Inthat case, the food and beverage product is prevented from rotting. Theantimicrobial agent may be utilized by adding it to a pharmaceutical, ormay be utilized as a pharmaceutical such as a therapeutic drug forinfection diseases or an antimicrobial chemotherapeutic remedy. Theantimicrobial agent may be utilized by adding it to cosmetics or aquasi-drug. In that case, it serves to keep the skin, the oral cavity,axilla and the like clean.

When the antimicrobial agent is used by adding it to a food and beverageproduct, a pharmaceutical, cosmetics or a quasi-drug, the concentrationof the flavanone compound contained in these products is preferably 10ppm or more, more preferably 20 ppm or more, still more preferably 30ppm to 10,000 ppm, and in particular preferably 50 ppm to 1,000 ppm.When the concentration of the flavanone compound is less than 10 ppm, anantimicrobial action can not be satisfactorily exerted. On the contrary,when the concentration is more than 10,000 ppm, it is uneconomical.

An antitumor agent according to the first embodiment contains theflavanone compound as an active ingredient, which is mainly utilized asa pharmaceutical. The dose of the antitumor agent is determined so thatthe concentration of the flavanone compound when the flavanone compoundacts upon cancer cells can be preferably 0.1 μM to 100 mM, and morepreferably 10 to 1,000 μM. When the concentration of the flavanonecompound is less than 0.1 μM, the therapeutic effect is weak. On thecontrary, when the concentration is more than 100 mM, it isuneconomical.

The dose of the antitumor agent for an adult is preferably 0.5 to 10 g,and more preferably 2 to 5 g in terms of the flavanone compound per day.When the daily dose of the flavanone compound is less than 0.5 g, itsantitumor action can not be satisfactorily exerted. On the contrary,when the daily dose is more than 10 g, it is uneconomical. The dose ofthe antitumor agent for a child is preferably about half of that for anadult.

When the flavanone compound is contained in a food and beverage product(for example, a health food product), cosmetics or a quasi-drug, thoseproducts may be utilized as products which exert cancer-preventiveeffects by promoting the physiological removal of undesired cells suchas a cancerating abnormal cell. When the product is a pharmaceutical,the concentration of the flavanone compound therein is preferably about1 to 50%, and more preferably about 10 to 30%.

A food and beverage product according to the first embodiment containsthe flavanone compound. The food and beverage product may contain theantioxidant or antimicrobial agent as mentioned above. Due to theantioxidant action of the flavanone compound contained in the food andbeverage product, the food and beverage product removes active oxygen invivo, and thus is utilized as a health food which exerts varioushealth-enhancement effects. The flavanone compound in the food andbeverage product also prevents the deterioration of the food andbeverage product due to the deterioration-inhibiting action of theflavanone compound so as to enhance the storage stability of the foodand beverage product, or prevents the food and beverage product fromrotting due to the antimicrobial action of the flavanone compound so asto enhance the storage stability of the food and beverage product.Therefore, the quality of the food and beverage product is stablymaintained over a long period of time. The flavanone compound in thefood and beverage product promotes, by its antitumor action, thephysiological removal of undesired cells such as a cancerating abnormalcell and an aged cell reaching its cellular life span. Thus the food andbeverage product is also utilized as a health food which exerts a highhealth-enhancement effect.

The intake of the food and beverage product for an adult is preferably0.05 to 10 g, and more preferably 0.2 to 5 g in terms of the flavanonecompound per day. When the daily intake of the flavanone compound isless than 0.05 g, the antioxidant action of the flavanone compound maynot be effectively exerted. On the contrary, when the daily intake ismore than 10 g, it is uneconomical.

The first embodiment has the following advantageous effects.

A flavanone compound of the first embodiment is5,7,3′,4′-tetrahydroxy-5′-C-geranylflavanone (isonymphaeol-B)represented by the structural formula 1 mentioned above. Since theflavanone compound has an antioxidant action, an antitumor action, anantimicrobial action and the like, it is used for a wide variety ofapplications, including a food and beverage product and apharmaceutical. In particular, the flavanone compound, which is a singlecompound, can simultaneously exert a multiple and multivalent action.Thus, the point that the flavanone compound is utilized as a rawmaterial for a multifunctional health-food as typified by a propolisproduct is worthy of note. Furthermore, the flavanone compound is usedfor a similar application as the one for eriodictyol, as well as forvarious applications wherein a higher lipophilic property than that oferiodictyol is utilized. Since the flavanone compound is contained in apropolis product which has been conventionally used as a health-foodraw-material, there is no problem with respect to oral ingestion andtranscutaneous administration.

An antioxidant of the first embodiment contains the flavanone compoundhaving a high antioxidant action, as an active ingredient. Therefore,the antioxidant, when added to a food and beverage product, cosmetics ora quasi-drug, prevents the deterioration thereof so as to enhance thestorage stability, as well as exerting a health-enhancement effect andan anti-aging effect in vivo when the antioxidant has been orallyingested or transcutaneously administered.

An antimicrobial agent of the first embodiment contains the flavanonecompound having a high antimicrobial action, as an active ingredient.Therefore, the antimicrobial agent, when added to a food and beverageproduct, cosmetics or a quasi-drug, prevents deterioration thereof so asto enhance the storage stability, as well as exerting a high sanitaryeffect and a high deodorant effect when the antimicrobial agent has beentranscutaneously administered as cosmetics or a quasi-drug. Theantimicrobial agent is also utilized as a pharmaceutical.

An antitumor agent of the first embodiment contains the flavanonecompound having a high antitumor action, as an active ingredient.Therefore, the antitumor agent exerts a high curative effect on acancer, as well as being expected to exert a preventive effect thereon.

A food and beverage product (a beverage or a food product) of the firstembodiment contains the flavanone compound having an antioxidant action,an antitumor action, an antimicrobial action and the like. Therefore,according to the food and beverage product, deterioration and rottennessof the food and beverage product itself is prevented, as well asmultiple and useful effects in vivo, such as a health-enhancementeffect, an anti-aging effect, a metabolism-enhancement effect and acancer-preventive effect, are simultaneously exerted. When the contentof the flavanone compound in a food and beverage product is set in arelatively small amount, a food and beverage product whose storagestability only has been enhanced by the deterioration-preventive orrottenness-preventive action of the flavanone compound is easilyobtained.

Hereinafter, a second embodiment of the present invention will beexplained.

A flavanone compound according to the second embodiment contains atleast one substance selected from nymphaeol-A, nymphaeol-B, andnymphaeol-C.

Nymphaeol-B is 5,7,3′,4′-tetrahydroxy-2′-C-geranylflavanone and isrepresented by the structural formula 2:

Nymphaeol-B has the molecular formula C₂₅H₂₈O₆, a molecular weight of424, and a melting point (MP) of 80 to 83° C. (see FIG. 1). Nymphaeol-Bis a naturally occurring organic compound, which has been isolated froman Okinawa propolis by the present inventors. Although nymphaeol-B has astructural characteristic similar to that of eriodictyol, it has aC-geranyl group at the 2′-position. Thus, it is higher in lipophilicproperties (or membrane permeabilities) than eriodictyol.

Nymphaeol-A is 5,7,3′,4′-tetrahydroxy-6-C-geranylflavanone and isrepresented by the structural formula 3:

Nymphaeol-A has the molecular formula C₂₅H₂₈O₆, a molecular weight of424, and a melting point (MP) of 172 to 175° C. (see FIG. 5).Nymphaeol-A is a naturally occurring organic compound, which has beenisolated from an Okinawa propolis by the present inventors. Althoughnymphaeol-A has a structural characteristic similar to that oferiodictyol, it has a C-geranyl group at the 6-position. Thus, it ishigher in lipophilic properties (or membrane permeabilities) thaneriodictyol.

Nymphaeol-C is5,7,3′,4′-tetrahydroxy-6-(3′″,3′″-dimethylallyl)-2′-C-geranylflavanoneand is represented by the structural formula 4:

Nymphaeol-C has the molecular formula C₃₀H₃₆O₆, and a molecular weightof 492 (see FIG. 7). Nymphaeol-C is a naturally occurring organiccompound, which has been isolated from an Okinawa propolis by thepresent inventors. Although nymphaeol-C has a structural characteristicsimilar to that of eriodictyol, it has a 3′″,3′″-dimethylallyl group atthe 6-position as well as a C-geranyl group at the 2′-position. Thus,nymphaeol-C is higher in lipophilic properties (or membranepermeabilities) than eriodictyol, nymphaeol-A and nymphaeol-B.

Any of nymphaeol-A, nymphaeol-B and nymphaeol-C has as high anantioxidant action as eriodictyol or α-tocopherol. Furthermore, any ofnymphaeol-A, nymphaeol-B and nymphaeol-C has an antitumor action whichinhibits the proliferation of cancer cells such as a breast cancer cell.The antitumor action of each of nymphaeol-A and nymphaeol-C is higherthan that of nymphaeol-B. Each of nymphaeol-A, nymphaeol-B andnymphaeol-C has an action inducing physiological cell-death (apotosis)in order to remove undesired cells such as a cancerating a abnormalcell, and an aged cell reaching its cellular life span. In addition,nymphaeol-B has an antimicrobial action on Gram-positive bacteria suchas Staphylococcus aureus, and spore forming bacteria such as GenusBacillus. Each of nymphaeol-A and nymphaeol-C has an antimicrobialaction on Gram-negative bacteria such as Escherichia coli, and theabove-mentioned Gram-positive bacteria and spore forming bacteria.

An antioxidant according to the second embodiment contains at least onekind selected from nymphaeol-A, nymphaeol-B and nymphaeol-C as an activeingredient (or an anti-oxidant component). The antioxidant may beutilized by adding it to a food and beverage product as a deteriorationinhibitor to effectively inhibit the deterioration (mainly, oxidationdeterioration) of various products, such as the oxidation deteriorationof fats and oils, the deterioration of flavor components, thedecomposition of coloring matter, and the discoloration of coloringmatter. In a living body wherein a food and beverage product such as ahealth food, containing the antioxidant, has been orally ingested, eachof nymphaeol-A, nymphaeol-B and nymphaeol-C eliminates active oxygen soas to exert health-enhancement effects such as an enhancement action forhepatic function, a decrease in acetaldehyde toxicity, an antioxidantaction for low-density lipoprotein-cholesterol (LDL), anproliferation-inhibiting action to breast cancer cells, and animprovement in immune function. The antioxidant may be utilized byallowing it to be contained in cosmetics or a quasi-drug. In that case,it serves for whitening effectiveness and aging protection and the likefor the skin, the oral cavity and the like.

An antimicrobial agent according to the second embodiment contains atleast one substance selected from nymphaeol-A, nymphaeol-B andnymphaeol-C as an active ingredient. The antimicrobial agent is utilizedby adding it to, for example, a food and beverage product. In that case,the food and beverage product is prevented from rotting. Theantimicrobial agent may be utilized by adding it to a pharmaceutical, ormay be utilized as a pharmaceutical such as a therapeutic drug forinfection diseases or an antimicrobial chemotherapeutic remedy. Theantimicrobial agent may be utilized by adding it to cosmetics or aquasi-drug. In that case, it serves to keep the skin, the oral cavity,axilla and the like clean.

When the antimicrobial agent is used by adding it to a food and beverageproduct, a pharmaceutical, cosmetics or a quasi-drug, the totalconcentration of nymphaeol-A, nymphaeol-B and nymphaeol-C contained inthese products is preferably 10 ppm or more, more preferably 15 ppm ormore, still more preferably 30 ppm to 10,000 ppm, and in particularlypreferably 50 ppm to 1,000 ppm. When the total concentration thereof isless than 50 ppm, antimicrobial action can not be satisfactorilyexerted. On the contrary, when the concentration is more than 10,000ppm, it is uneconomical.

An antitumor agent according to the second embodiment contains at leastone substance selected from nymphaeol-A, nymphaeol-B and nymphaeol-C asan active ingredient, which is mainly utilized as a pharmaceutical. Thedose of the antitumor agent is determined so that the totalconcentration of nymphaeol-A, nymphaeol-B and nymphaeol-C whennymphaeol-A, nymphaeol-B and nymphaeol-C act upon cancer cells can bepreferably 0.1 μM to 100 mM, and more preferably 10 to 1,000 μM. Whenthe total concentration thereof is less than 0.1 μM, the therapeuticeffect is weak. On the contrary, when it is more than 100 mM, it isuneconomical.

The dose of the antitumor agent for an adult is preferably 0.5 to 10 g,and more preferably 2 to 5 g in terms of nymphaeol-A, nymphaeol-B andnymphaeol-C per day. When the daily dose of nymphaeol-A, nymphaeol-B andnymphaeol-C is less than 0.5 g, their antitumor actions can not besatisfactorily exerted. On the contrary, when it is more than 10 g, itis uneconomical. The dose of nymphaeol-A, nymphaeol-B and nymphaeol-Cfor a child is preferably about half of that for an adult.

When at least one substance selected from nymphaeol-A, nymphaeol-B andnymphaeol-C is contained in a food and beverage product (for example, ahealth food product), cosmetics or a quasi-drug, those products may beutilized as products that exert cancer-preventive effects by promotingthe physiological removal of undesired cells such as a canceratingabnormal cell. When the product is a pharmaceutical, the totalconcentration of nymphaeol-A, nymphaeol-B and nymphaeol-C therein ispreferably about 1 to 50%, and more preferably about 10 to 30%.

A food and beverage product according to the second embodiment containsat least one substance selected from nymphaeol-A, nymphaeol-B andnymphaeol-C. The food and beverage product may be contains theantioxidant or antimicrobial agent as mentioned above. Due to theantioxidant action of nymphaeol-A, nymphaeol-B and nymphaeol-C containedin the food and beverage product, the food and beverage product removesactive oxygen in vivo, and thus is utilized as a health food whichexerts various health-enhancement effects. Nymphaeol-A, nymphaeol-B andnymphaeol-C in the food and beverage product also prevents thedeterioration of the food and beverage product due to thedeterioration-inhibiting action thereof so as to enhance the storagestability of the food and beverage product, or prevents the food andbeverage product from rotting due to the antimicrobial action thereof soas to enhance the storage stability of the food and beverage product.Therefore, the quality of the food and beverage product is stablymaintained over a long period of time. Nymphaeol-A, nymphaeol-B andnymphaeol-C in the food and beverage product promotes, by theirantitumor actions, the physiological removal of undesired cells such asa cancerating abnormal cell and an aged cell reaching its cellular lifespan. Thus, the food and beverage product is also utilized as a healthfood which exerts a high health-enhancement effect.

The intake of the food and beverage product for an adult is preferably0.05 to 10 g, and more preferably 0.2 to 5 g in terms of nymphaeol-A,nymphaeol-B and nymphaeol-C per day. When the daily intake ofnymphaeol-A, nymphaeol-B and nymphaeol-C is less than 0.05 g, theantioxidant action thereof may not be effectively exerted. On thecontrary, when the daily intake is more than 10 g, it is uneconomical.

The second embodiment has the following advantageous effects.

Since any of nymphaeol-A, nymphaeol-B and nymphaeol-C has an antioxidantaction, an antitumor action and an antimicrobial action, it is used fora wide variety of applications, including a food and beverage productand a pharmaceutical. In particular, each of nymphaeol-A, nymphaeol-Band nymphaeol-C, which is a single compound, can simultaneously exert amultiple and multivalent action. Thus, the point that each ofnymphaeol-A, nymphaeol-B and nymphaeol-C is utilized as a raw materialfor a multifunctional health-food as typified by a propolis product isworthy of note. Furthermore, nymphaeol-A, nymphaeol-B and nymphaeol-C isused for a similar application to the one for eriodictyol, as well asfor various applications wherein a higher lipophilic property than thatof eriodictyol is utilized. Since nymphaeol-A, nymphaeol-B ornymphaeol-C is contained in a propolis product which has beenconventionally used as a raw material for health food products, there isno problem with respect to oral ingestion and transcutaneousadministration.

An antioxidant of the second embodiment contains, as an activeingredient, at least one substance selected from nymphaeol-A,nymphaeol-B and nymphaeol-C, each of which has a high antioxidantaction. Therefore, the antioxidant, when added to a food and beverageproduct, cosmetics or a quasi-drug, prevents the deterioration thereofso as to enhance the storage stability, as well as exerts ahealth-enhancement effect and an anti-aging effect in vivo when theantioxidant has been orally ingested or transcutaneously administered.

An antimicrobial agent of the second embodiment contains, as an activeingredient, at least one substance selected from nymphaeol-A,nymphaeol-B and nymphaeol-C, each of which has a high antimicrobialaction. Therefore, the antimicrobial agent, when added to a food andbeverage product, cosmetics or a quasi-drug, prevents deteriorationthereof so as to enhance storage stability, as well as exerts a highsanitary effect and a high deodorant effect when the antimicrobial agenthas been transcutaneously administered as cosmetics or a quasi-drug. Theantimicrobial agent is also utilized as a pharmaceutical.

An antitumor agent of the second embodiment contains, as an activeingredient, at least one substance selected from nymphaeol-A,nymphaeol-B and nymphaeol-C, each of which has a high antitumor action.Therefore, the antitumor agent exerts a high curative effect on acancer, as well as is expected to exert a preventive effect thereon.

A food and beverage product (a beverage or food product) of the secondembodiment contains at least one substance selected from nymphaeol-A,nymphaeol-B and nymphaeol-C, each of which has an antioxidant action, anantitumor action, an antimicrobial action and the like. Therefore,according to the food and beverage product, the deterioration androttenness of the food and beverage product itself are prevented, aswell as multiple and useful effects in vivo, such as ahealth-enhancement effect, an anti-aging effect, ametabolism-enhancement effect and a cancer-preventive effect, aresimultaneously exerted. When the content of nymphaeol-A, nymphaeol-B andnymphaeol-C in a food and beverage product is set in a relatively smallamount, a food and beverage product whose storage stability only hasbeen enhanced by the deterioration-preventive or rottenness-preventiveaction of nymphaeol-A, nymphaeol-B and nymphaeol-C is easily obtained.

Hereinafter, the present invention will be more specifically explainedby reference to Examples.

<Isolation of Compounds>

To 50 g of an Okinawa propolis raw material, 500 ml of ethanol wasadded, followed by an ultrasonic treatment for several minutes. Thesolution was stirred at room temperature overnight, and the residualmaterial was removed through filtration. The resultant extract wasconcentrated under reduced pressure to obtain 39.73 g of an ethanolextract. Thereafter, the ethanol extract was subjected to columnchromatography under the condition as described below, whereby elevenfractions were obtained, which were eluted with the elution solvents ofthe following (1) to (11).

-   -   Column Tube: glass column, 5.0×45 cm    -   Filler: silica gel, approximately 590 cm³    -   Elution Solvents:        -   (1) hexane:ethyl acetate=90:10 (350 ml)        -   (2) hexane:ethyl acetate=80:20 (220 ml)        -   (3) hexane:ethyl acetate=70:30 (250 ml)        -   (4) hexane:ethyl acetate=60:40 (1000 ml)        -   (5) hexane:ethyl acetate=50:50 (200 ml)        -   (6) hexane:ethyl acetate=40:60 (100 ml)        -   (7) hexane:ethyl acetate=30:70 (100 ml)        -   (8) hexane:ethyl acetate=20:80 (100 ml)        -   (9) hexane:ethyl acetate=10:90 (100 ml)        -   (10) ethyl acetate (200 ml)        -   (11) methanol (700 ml)

When each of the obtained fractions was analyzed under the followingHPLC condition 1, it has been confirmed that four main ingredients arecontained in the fraction (referred to as “the fourth fraction”) whichwas eluted with the elution solvent (4).

HPLC Condition 1

-   -   Column: YMC-Pack R&D ODS (4.6×250 mm)    -   Solvent: A: water (with 2% of acetic acid),        -   B: acetonitrile (with 2% of acetic acid)    -   Elution Condition:        -   0-60 min (gradient elution; A:B=80:20→20:80)    -   Flow Rate: 1 ml/min    -   Detection: UV 280 nm

Then, the fourth fraction was used so as to separate and purify it underthe following HPLC condition 2, whereby Compound 1 (yield: 61.1 mg),Compound 2 (yield: 65.7 mg) and Compound 3 (yield: 99.8 mg) wereisolated. Furthermore, the fourth fraction was used so as to separateand purify it under the following HPLC condition 3, whereby Compound 4(yield: 20.0 mg) was isolated.

HPLC Condition 2

-   -   Column: YMC-Pack R&D ODS (20×250 mm)    -   Solvent: water (with 0.1% of TFA): acetonitrile        -   (with 0.1% of TFA)=40:60    -   Flow Rate: 9 ml/min    -   Detection: UV 280 nm

HPLC Condition 3

-   -   Column: YMC-Pack R&D ODS (20×250 mm)    -   Solvent: water (with 0.1% of TFA): acetonitrile        -   (with 0.1% of TFA)=20:80    -   Flow Rate: 9 ml/min    -   Detection: UV 280 nm

<Identification of Compounds 1 to 4>

The structure of each of Compounds 1 to 4 was analyzed by using ¹H-NMR,¹³C-NMR, MS, IR spectrum, UV spectrum, and the like.

(Compound 1)

The physicochemical properties of Compound 1 are shown in FIG. 1. Fromthe ESI-MS measurement, it was confirmed that the molecular weight ofCompound 1 was 424. From the IR spectrum, it was suggested that therewere a hydroxyl group at 3420 cm⁻¹ and a carbonyl group at 1680 cm⁻¹,and the UV spectrum showed a characteristic spectrum of flavanone orflavanol, whereby Compound 1 was presumed to have a flavanone skeleton.From the integrated value of the ¹H-NMR spectrum, the existence of 28protons was identified, while from the ¹³C-NMR spectrum, 25 signals wereobserved. From the DEPT spectrum, three methyl groups, four methylenegroups, seven methine groups and eleven quaternary-carbon atoms wereidentified. From the results mentioned above, the molecular formula ofCompound 1 was presumed to be C₂₅H₂₈O₆. Furthermore, from the NMR datashown in FIG. 2, concerning the HSQC spectrum, the ¹H-¹H COSY, the HMBCspectrum, the CD spectrum, and the like, Compound 1 was identified asnymphaeol-B (5,7,3′,4′-tetrahydroxy-2′-C-geranylflavanone) representedby the structural formula (2) mentioned above. Although the isolation ofthis compound from Hernandia nymphaefolia(presl) Kubitzki has beenalready reported, the isolation of this compound from propolis has beencarried out by this study for the first time.

(Compound 2)

The physicochemical properties of Compound 2 are shown in FIG. 3. Fromthe ESI-MS measurement, it was confirmed that the molecular weight ofCompound 2 was 424. From the IR spectrum, it was suggested that therewere a hydroxyl group at 3360 cm⁻¹ and a carbonyl group at 1680 cm⁻¹,and the UV spectrum showed a characteristic spectrum of flavanone orflavanol, whereby Compound 2 was presumed to have a flavanone skeleton.From the integrated value of the ¹H-NMR spectrum, the existence of 28protons was confirmed, while from the ¹³C-NMR spectrum, 25 signals wereobserved. From the DEPT spectrum, three methyl groups, four methylenegroups, eight methine groups and eleven quaternary-carbon atoms wereidentified. From the results mentioned above, the molecular formula ofCompound 2 was presumed to be C₂₅H₂₈O₆. Furthermore, from the NMR datashown in FIG. 4, concerning the HSQC spectrum, the ¹H-¹H COSY, the HMBCspectrum, the CD spectrum, and the like, Compound 2 was identified as5,7,3′,4′-tetrahydroxy-5′-C-geranylflavanone represented by thestructural formula (1) mentioned above. This compound was a new compoundwhich had not been heretofore disclosed in the literature or the like.

(Compound 3)

The physicochemical properties of Compound 3 are shown in FIG. 5. Fromthe ESI-MS measurement, it was confirmed that the molecular weight ofCompound 3 was 424. From the IR spectrum, it was suggested that therewere a hydroxyl group at 3380 cm⁻¹ and a carbonyl group at 1680 cm⁻¹,and the UV spectrum showed a characteristic spectrum of flavanone orflavanol, whereby Compound 3 was presumed to have a flavanone skeleton.From the integrated value of the ¹H-NMR spectrum, the existence of 28protons was confirmed, while from the ¹³C-NMR spectrum 25 signals wereobserved. From the DEPT spectrum, the existence of three methyl groups,four methylene groups, seven methine groups and eleven quaternary-carbonatoms was confirmed. From the results mentioned above, the molecularformula of Compound 3 was presumed to be C₂₅H₂₈O₆. Furthermore, from theNMR data shown in FIG. 6, concerning the HSQC spectrum, the ¹H-¹H COSY,the HMBC spectrum, the CD spectrum, and the like, Compound 3 wasidentified as nymphaeol-A (5,7,3′,4′-tetrahydroxy-6-C-geranylflavanone)represented by the structural formula (3) mentioned above. Although theisolation of this compound from Hernandia nymphaefolia(presl) Kubitzkiand Mimulus clevelandii has been already reported, the isolation of thiscompound from propolis has been carried out by this study for the firsttime.

(Compound 4)

The physicochemical properties of Compound 4 are shown in FIG. 7. Fromthe FAB-MS measurement, it was confirmed that the molecular weight ofCompound 4 was 492. From the IR spectrum, it was suggested that therewere a hydroxyl group at 3400 cm⁻¹ and a carbonyl group at 1640 cm⁻¹,and the UV spectrum showed a characteristic spectrum of flavanone orflavanol, whereby Compound 4 was presumed to have a flavanone skeleton.From the integrated value of the ¹H-NMR spectrum, the existence of 36protons was confirmed, while from the ¹³C-NMR spectrum, the existence of30 carbon atoms was observed. From the DEPT spectrum, the existence offive methyl groups, five methylene groups, seven methylene groups, andthirteen quaternary-carbon atoms was confirmed. From the resultsmentioned above, the molecular formula of Compound 4 was presumed to beC₃₀H₃₆O₆. Furthermore, from the NMR data shown in FIG. 8, concerning theHSQC spectrum, the ¹H-¹H COSY, the HMBC spectrum, the CD spectrum, andthe like, Compound 4 was identified as nymphaeol-C(5,7,3′,4′-tetrahydroxy-6-(3′″,3′″-dimethylallyl)-2′-C-geranylflavanone)represented by the structural formula (4) mentioned above. Although theisolation of this compound from Hernandia nymphaefolia(presl) Kubitzki,and Macaranga tanarius has been already reported, the isolation of thiscompound from propolis has been carried out by this study for the firsttime.

<Measurement of Contents in Propolis>

With respect to the fact of how much of Compounds 1 to 4 are containedin an Okinawa propolis, analysis was conducted under the following HPLCcondition 4 so as to determine the content of each of Compounds 1 to 4.As a result, it has been confirmed that 12.7 g of Compound 1, 10.5 g ofCompound 2, 13.5 g of Compound 3, and 9.1 g of Compound 4 are containedin 100 g of raw material of Okinawa propolis.

HPLC Condition 4

-   -   Column: YMC-Pack R&D ODS (4.6×250 mm)    -   Solvent: A: water (with 0.1% of TFA),        -   B: acetonitrile (with 0.1% of TFA),    -   Elution Conditions:        -   0-50 min (gradient elution; A:B=65:35<0:100)    -   Flow Rate: 1 ml/min    -   Detection: UV 280 nm

<DPPH Radical Scavenging Activity Test>

DPPH (α,α-diphenyl-β-picrylhydradil) is a purple stable radical having amaximum absorption at 517 nm, which is converted into colorlesshydrazine by gaining hydrogen. This color reaction was utilized so as todetermine the radical scavenging activity of each of Compounds 1 to 4and the like. That is, each of Compounds 1 to 4 was dissolved in ethanolto prepare 3 ml of a sample solution having a concentration of 25 μM.Thereafter, to each of the resultant sample solutions, 0.75 ml of a 0.5mM DPPH solution (whose solvent was ethanol) was added and stirred, andreacted in a dark place for one hour, followed by the determination ofan absorbance at 517 nm. Furthermore, in place of Compounds 1 to 4, BHT(butylated hydroxytoluene), α-tocopherol or eriodictyol was used so asto determine an absorbance according to a similar procedure to theabove. Besides, instead of the above sample solutions, ethanol was usedas a control so as to determine an absorbance according to a similarprocedure to the above. Then the radical scavenging activity (%) of eachof the materials was calculated using the following calculationformula 1. The results are shown in the following Table 1. Incidentally,each of values shown in Table 1 is the average value and standarddeviation of values obtained from three runs.(Radical Scavenging Activity)=[{(Absorbance of Control)−(Absorbance ofSample Solution)}/(Absorbance of Control)]×100  Calculation Formula 1TABLE 1 Radical Scavenging Activity (%) from DPPH Antioxidant ActivityRadical Scavenging (%) from β-carotene Sample Activity Test Fading TestCompound 1 55.35 ± 0.43 85.54 ± 2.24 Compound 2 49.86 ± 0.96 78.07 ±1.79 Compound 3 64.00 ± 0.58 60.62 ± 1.16 Compound 4 50.79 ± 0.08 80.06± 0.29 BHT 28.51 ± 7.48 85.02 ± 1.89 α-tocopherol 58.87 ± 1.24 93.00 ±0.73 Eriodictyol 68.82 ± 1.12 81.47 ± 2.48

From the results shown in Table 1, it has been clarified that each ofCompounds 1 to 4 has a higher radical scavenging activity than that ofBHT, and has about the same radical scavenging activity as that ofα-tocopherol. Among others, Compound 3 had the highest radicalscavenging activity, which was about the same as that of eriodictyol.Although each of Compounds 1, 3 and 4 is a known material, the radicalscavenging activity thereof has not been conventionally studied. Theremarkably high radical scavenging activity of each of Compounds 1, 3and 4 has been clarified by this study for the first time.

<β-Carotene Fading Test>

β-carotene will fade due to the reaction of linoleic acid peroxide,which is produced by the autoxidation of linoleic acid, with a doublebond in β-carotene. This phenomenon was utilized so as to determine theantioxidant activity of each of Compounds 1 to 4 and the like. That is,first of all, 2 ml of a 200 mg/ml solution of Tween-40 in chloroform,0.4 ml of a 100 mg/ml solution of linoleic acid in chloroform, and 3 mlof a 0.1 mg/ml solution of β-carotene in chloroform were mixed, andthereafter the solvent was removed by using a nitrogen gas.Subsequently, 100 ml of distilled water was added thereto, andadequately stirred to obtain an emulsion. To 3 ml of this emulsion,ethanol was added to completely dissolve the solute in the solvent.Thereafter, each of Compounds 1 to 4 was dissolved in ethanol so as toprepare a sample solution having a concentration of 1.2 mM. 50 μl of thesample solution was mixed with the above emulsion wherein the solute hadbeen completely dissolved so as to prepare a reaction liquid (or asample reaction liquid). Then the concentration of each of Compounds 1to 4 in the reaction liquid was 20 μM. The reaction liquid was incubatedat 60° C. for 60 minutes. Then the absorbance of each of the reactionliquid before the incubation and the reaction liquid after theincubation was determined at 470 nm. Furthermore, BHT, α-tocopherol, oreriodictyol was used in place of Compounds 1 to 4 so as to determine theabsorbance of the reaction liquid before and after incubation accordingto a similar procedure to the above-mentioned one. In addition, as acontrol, a reaction liquid (or a control reaction liquid) wherein nosample solution was contained was prepared so as to determine theabsorbance of the reaction liquid before and after incubation accordingto a similar procedure to the above-mentioned one. The antioxidantactivity (%) of each of the materials was calculated using the followingcalculation formula 2. The results are shown in Table 1 described above.Incidentally, each of values shown in Table 1 is the average value andstandard deviation of values obtained from three runs.(Antioxidant Activity)=[{(Fading Rate of Control)−(Fading Rate of SampleSolution)}/(Fading Rate of Control)]×100  Calculation Formula 2

It should be noted that in the calculation formula 2, “Fading Rate ofControl” is the natural logarithm of a value which is acquired bydividing the absorbance of the control reaction liquid before incubationby the absorbance of the control reaction liquid after incubation andfurther by dividing the resultant value by 60; and “Fading Rate ofSample Solution” is the natural logarithm of a value which is acquiredby dividing the absorbance of the sample reaction liquid beforeincubation by the absorbance of the sample reaction liquid afterincubation and further by dividing the resultant value by 60.

From the results as shown in Table 1, it has been confirmed thatCompound 2 has about the same high antioxidant activity as that of eachof BHT, α-tocopherol, and eriodictyol.

From the results as shown in Table 1, it has been confirmed that any ofCompounds 1 to 4 has a high antioxidant activity, and among them,Compounds 1, 2 and 4 have about the same high antioxidant activity asthat of each of BHT, α-tocopherol, and eriodictyol. Although each ofCompounds 1, 3 and 4 is a known material, the antioxidant activitythereof has not been conventionally studied. The remarkably highantioxidant activity of each of Compounds 1, 3 and 4 has been clarifiedby this study for the first time.

<Breast Cancer Cell Proliferation-Inhibition Test>

When breast cancer cells (MCF-7) are cultured, if estradiol (or17β-estradiol) having a cell-proliferation accelerating action, is addedthereto, the proliferation of breast cancer cells can be simply promotedin a short period. This phenomenon was utilized so as to examine theeffect of each of Compounds 1 to 4 and the like on the proliferationinhibition of breast cancer cells. That is, first of all, each ofCompounds 1 to 4 was diluted with dimethyl sulfoxide to prepare a samplesolution. Thereafter, 2×10³ of MCF-7 were inoculated in each well of a96-well plate, and estradiol and the sample solution were added theretoafter 4 hours. Estradiol was added to each compartment so that the finalconcentration of estradiol can be 0.1 nM, and the final concentration ofthe sample solution can be 0.2 μM, 2 μM, or 20 μM. After incubation fora predetermined period of time (three or five days), each of the mediawas replaced with a new medium, and an enzyme solution (Cell countingKit-8: Wako) was added to the new medium in an amount of 10% of the newmedium. After maintained the medium in an incubator at a temperature of37° C. for two hours, the absorbance of the medium was determined at awavelength of 450 nm (a reference wave length of 630 nm) by means of aspectrophotometer so as to quantify the number of living cells in eachcompartment.

As for the compartment whose incubation period is predetermined to befive days, on the third day of the incubation, the medium was replacedwith a new medium, and thereafter, estradiol and a sample solution wereadded to the new medium, and the incubation was continued till fifthday. As for the compartment whose incubation period is predetermined tobe 0 day, at four hours after the cells were inoculated, an enzymesolution was added to the medium. The medium was maintained in anincubator at a temperature of 37° C. for two hours, followed bydetermining the absorbance.

Instead of Compounds 1 to 4, eriodictyol was used to determine theabsorbance according to a similar procedure to the above-mentioned one,and thus the number of living cells in each compartment was quantified.Furthermore, Control 1 to which neither estradiol nor a sample had beenadded was used to determine the absorbance according to a similarprocedure to the above-mentioned one, and thus the number of livingcells in each compartment was quantified, while Control 2 to which nosample had been added was used to determine the absorbance according toa similar procedure to the above-mentioned one, and thus the number ofliving cells in each compartment was quantified.

When it is assumed that the number of living cells of Control 1 asquantified after a zero-day incubation period is 1, the relative valueof living cells as quantified in each of the runs mentioned above isshown in Table 2. Incidentally, each of values shown in Table 2 is theaverage value and standard deviation of values obtained from eightwells. TABLE 2 Relative Value of Living Cells After 3-days After 5-daysOn 0-day Incubation Incubation Sample Incubation Period Period Control 11.00 ± 0.07 2.45 ± 0.12 3.29 ± 0.08 Control 2 (0.1 nM Estradiol) 0.97 ±0.04 3.12 ± 0.34 7.02 ± 0.99 Eriodictyol 0.2 μM 0.96 ± 0.04 2.88 ± 0.227.33 ± 0.60 2 μM 0.98 ± 0.07 2.90 ± 0.13 7.16 ± 0.36 20 μM 1.01 ± 0.052.54 ± 0.30 5.13 ± 0.62 Compound 1 0.2 μM 0.98 ± 0.04 2.86 ± 0.14 7.26 ±0.48 2 μM 0.99 ± 0.05 2.58 ± 0.11 6.01 ± 0.25 20 μM 1.01 ± 0.05 2.22 ±0.19 4.17 ± 0.50 Compound 2 0.2 μM 0.95 ± 0.04 2.97 ± 0.37 6.83 ± 0.58 2μM 0.99 ± 0.04 2.68 ± 0.19 6.59 ± 0.50 20 μM 1.00 ± 0.07 2.59 ± 0.215.59 ± 1.01 Compound 3 0.2 μM 0.99 ± 0.05 2.94 ± 0.20 6.99 ± 0.66 2 μM1.01 ± 0.05 2.53 ± 0.30 5.38 ± 0.44 20 μM 0.96 ± 0.04 1.21 ± 0.22 0.89 ±0.12 Compound 4 0.2 μM 0.99 ± 0.04 2.97 ± 0.27 6.30 ± 0.54 2 μM 1.00 ±0.07 3.03 ± 0.30 6.41 ± 0.53 20 μM 0.98 ± 0.04 1.27 ± 0.20 1.01 ± 0.12

From the results shown in Table 2, it has been confirmed that each ofCompounds 1 to 4 has the effect of inhibiting the proliferation ofbreast cancer cells with differences somewhat therebetween. Furthermore,it has been found that the effect of each Compounds 1 to 4 on inhibitingthe proliferation of breast cancer cells depends upon its concentration.In particular, as for compartments to which 20 μM of Compound 3 or 4 hasbeen added, a more strongly inhibiting effect on the proliferation ofbreast cancer cells (i.e., a cytotoxic effect upon breast cancer cells)than that of Control 1 was confirmed. Although each of Compounds 1, 3and 4 is a known material, the breast cancer cells proliferationinhibiting action thereof has not been conventionally studied. Theremarkably high antitumor activity of each of Compounds 1, 3 and 4 hasbeen clarified by this study for the first time.

<Antimicrobial Activity Test with Ethanol Extract>

E. coli (IFO3366) as a biological indicator for Gram-negative bacteria;Staphylococcus aureus (IFO15035) as a biological indicator forGram-positive bacteria; Bacillus cereus (IFO15305T) as a biologicalindicator for spore forming bacteria having resistance properties evento a process such as thermal sterilization; and Bacillus coagulansseparated from a deteriorated canned food, as a biological indicator forfungi which cause the deterioration of a canned food were used so as toevaluate the antimicrobial activity of each of Compounds 1 to 4. Thatis, first of all, an ethanol extract from a raw material of propolis(see the Section <Isolation of Compounds>) was dissolved in 70% ethanol,and thereafter, standard agar media were prepared wherein theconcentration of the extract was adjusted to be 0 ppm, 12.5 ppm, 25 ppm,50 ppm, 100 ppm, or 150 ppm. Subsequently, these standard agar mediawere subjected to autoclave sterilization so as to prepare evaluationmedia, and each of the biological indicators was inoculated in each ofthese evaluation media so as to check out its growth and development. Asa result, it has been confirmed that the higher the concentration of theethanol extract is, the more strongly the growth and development of eachof the biological indicators is inhibited. In particular, when theconcentration of the ethanol extract is 30 ppm or more, or 50 ppm ormore, no biological indicators were detected from the media.Incidentally, it was previously confirmed that 70% ethanol had almost noeffect upon the growth and development of each of the biologicalindicators.

<Antimicrobial Activity Test with Compounds 1 to 4>

E. coli and Salmonella enteritidis (S. en; NBRC3313) as a biologicalindicator for Gram-negative bacteria; Staphylococcus aureus (Sta.) as abiological indicator for Gram-positive bacteria; and Bacillus cereus (B.ce) as a biological indicator for spore forming bacteria were used toevaluate the antimicrobial activity of each of Compounds 1 to 4. Thatis, first of all, each of Compounds 1 to 4 was dissolved in 70% ethanol,and thereafter, standard agar media were prepared wherein theconcentration of each of Compounds 1 to 4 was adjusted to be 0 ppm, 5ppm, 10 ppm, 15 ppm, 20 ppm, or 50 ppm. Subsequently, these standardagar media were subjected to autoclave sterilization so as to prepareevaluation media, and each of the biological indicators was inoculatedin each of these evaluation media. After the incubation of each of thebacteria, the number of the bacteria per a petri dish (CFU/petri dish)was determined. The results are shown in Tables 3 and 4. TABLE 3 Numberof Bacteria (CFU/petri dish) Gram- Spore Gram-negative positive formingConcentration of Bacteria Bacteria Bacteria Sample E. coli S. en Sta. B.ce 0 ppm >3000 >3000 470 13 Compound 1 5 ppm >3000 >3000 344 12 10ppm >3000 >3000 36 0 15 ppm >3000 >3000 0 0 20 ppm >3000 >3000 0 0 50ppm >3000 >3000 0 0 Compound 2 5 ppm >3000 >3000 395 17 10ppm >3000 >3000 108 0 15 ppm >3000 >3000 22 0 20 ppm >3000 >3000 0 0 50ppm >3000 >3000 0 0

TABLE 4 Number of Bacteria (CFU/petri dish) Gram- Spore Gram-negativepositive forming Concentration of Bacteria Bacteria Bacteria Sample E.coli S. en Sta. B. ce 0 ppm 5 221 202 183 Compound 3 5 ppm 3 296 22 4 10ppm 1 207 0 0 15 ppm 0 116 0 0 20 ppm 0 143 0 0 50 ppm 0 43 0 0 Compound4 5 ppm 6 249 26 16 10 ppm 6 199 7 0 15 ppm 9 225 10 0 20 ppm 6 132 1 050 ppm 0 65 0 0

From the results as shown in Table 3, it has been found that the higherthe concentration of Compound 1 or 2 is, the more strongly the growthand development of each of Gram-positive bacteria and spore formingbacteria is inhibited. Furthermore, it has been found that any of theconcentrations of Compound 1 and any of the concentrations of Compound 2have little effect upon the growth and development of each of E. coliand S. en. In addition, from this result it can be found that whenCompound 1 or 2 as an antimicrobial ingredient is contained in a foodand beverage product, a pharmaceutical, cosmetics or a quasi-drug, theconcentration of Compound 1 or 2 in these products is preferably 10 ppmor more, and more preferably 15 ppm or more.

From the results as shown in Table 4, it has been found that each ofCompounds 3 and 4 has an antimicrobial activity to any of the biologicalindicators, and in particular has a high antimicrobial activity to E.coli, Sta. and B. ce. Furthermore, from these results it can be alsofound that when Compound 3 as an antimicrobial ingredient is containedin a food and beverage product, a pharmaceutical, cosmetics or aquasi-drug, the concentration of Compound 3 in these products ispreferably 10 ppm or more, and more preferably 15 ppm or more. Besides,from these results it can be also found that when Compound 4 as anantimicrobial ingredient is contained in a food and beverage product, apharmaceutical, cosmetics or a quasi-drug, the concentration of Compound4 in these products is preferably 10 ppm or more, and more preferably 50ppm or more. Be noted that it was previously confirmed that 70% ethanolhad little effect upon the growth and development of each of thebiological indicators.

1. A flavanone compound comprising a structure represented by thestructural formula:


2. An antioxidant comprising a flavanone compound according to claim 1.3. An antimicrobial agent comprising a flavanone compound according toclaim
 1. 4. An antitumor agent comprising a flavanone compound accordingto claim
 1. 5. A food and beverage product comprising a flavanonecompound according to claim
 1. 6. The food and beverage productaccording to claim 5, wherein the concentration of the flavanonecompound contained in the food and beverage product is 50 ppm or more.7. The food and beverage product according to claim 5, wherein theconcentration of the flavanone compound contained in the food andbeverage product is 50 ppm to 10,000 ppm.
 8. A cosmetic comprising aflavanone compound according to claim
 1. 9. A quasi-drug comprising aflavanone compound according to claim
 1. 10. A pharmaceutical comprisinga flavanone compound according to claim
 1. 11. An antioxidant comprisingat least one flavanone compound selected from nymphaeol-A, nymphaeol-Band nymphaeol-C.
 12. An antimicrobial agent comprising at least oneflavanone compound selected from nymphaeol-A, nymphaeol-B andnymphaeol-C.
 13. An antitumor agent comprising at least one flavanonecompound selected from nymphaeol-A, nymphaeol-B and nymphaeol-C.
 14. Afood and beverage product comprising at least one flavanone compoundselected from nymphaeol-A, nymphaeol-B and nymphaeol-C.
 15. The food andbeverage product according to claim 14, wherein the concentration of theflavanone compound contained in the food and beverage product is 30 ppmor more.
 16. The food and beverage product according to claim 14,wherein the concentration of the flavanone compound contained in thefood and beverage product is 30 ppm to 10,000 ppm.
 17. A cosmeticcomprising at least one flavanone compound selected from nymphaeol-A,nymphaeol-B and nymphaeol-C.
 18. A quasi-drug comprising at least oneflavanone compound selected from nymphaeol-A, nymphaeol-B andnymphaeol-C.
 19. A pharmaceutical comprising at least one flavanonecompound selected from nymphaeol-A, nymphaeol-B and nymphaeol-C.